Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

The FDA Aims To Strike Balance On Inspecting Physicians Who Compound Drugs

Executive Summary

Just how much will the FDA look the other way when it comes to inspecting physician compounders?

You may also be interested in...



The FDA Sticks With Plan To Exercise Discretion In Enforcing Physician Compounding

Physicians who compound drugs in their offices for patients will not be inspected as FDA decides to exercise discretion, recent final guidance said.

Compounders Gain Flexibility In Quality Standards Due To PPE Shortages

The US FDA will allow pharmacy compounders to use non-sterile masks and gloves in cleanrooms, but risk strategies must be in place to ensure products are as contaminant-free as possible. Discretion responds to the current shortage of protective gear  due to the COVID-19 pandemic.

FDA Announces Wide-Ranging List of Compounding Priorities for 2019

FDA has announced a multifaceted effort to tackle the oversight of drug compounding facilities this year. On the to do list: setting the groundwork for establishing centers for excellence for outsourcing facilities; finalizing a guidance on identifying insanitary conditions at drug compounding facilities, and finalizing a memorandum of understanding targeting traditional compounders that distribute an “inordinate” amount of their compounded drugs across state lines.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS140649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel